Current status of the epidemiology of heart failure

Kannel, William B.

doi:10.1007/s11886-999-0035-7

Cited by 17 publications

(16 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 High BP increases the risk of total mortality; mortality due to heart disease, stroke, chronic kidney disease, and heart failure; and morbidity associated with nonfatal cardiovascular disease (CVD) events. 2 On the basis of estimates of population-attributable fractions, high BP may account for 27% of total CVD events in women and 37% in men, 4 14% of myocardial infarctions in men and 30% in women, 5 35% of ischemic strokes, 6 39% of chronic heart failure events in men and 59% in women, 7 and 56% of chronic kidney disease. 8 These results, based on North American populations, are supported by global estimates.…”

Section: Health and Economic Consequences Of Hypertension And Its Inamentioning

confidence: 99%

Call to Action on Use and Reimbursement for Home Blood Pressure Monitoring

Pickering¹,

Miller

Ogedegbe³

et al. 2008

Hypertension

487

235

View full text Add to dashboard Cite

Abstract-Home blood pressure monitoring (HBPM) overcomes many of the limitations of traditional office blood pressure (BP) measurement and is both cheaper and easier to perform than ambulatory BP monitoring. Monitors that use the oscillometric method are currently available that are accurate, reliable, easy to use, and relatively inexpensive. An increasing number of patients are using them regularly to check their BP at home, but although this has been endorsed by national and international guidelines, detailed recommendations for their use have been lacking. There is a rapidly growing literature showing that measurements taken by patients at home are often lower than readings taken in the office and closer to the average BP recorded by 24-hour ambulatory monitors, which is the BP that best predicts cardiovascular risk. Because of the larger numbers of readings that can be taken by HBPM than in the office and the elimination of the white-coat effect (the increase of BP during an office visit), home readings are more reproducible than office readings and show better correlations with measures of target organ damage. In addition, prospective studies that have used multiple home readings to express the true BP have found that home BP predicts risk better than office BP (Class IIa; Level of Evidence A). This call-to-action article makes the following recommendations: (1) It is recommended that HBPM should become a routine component of BP measurement in the majority of patients with known or suspected hypertension; (2) Patients should be advised to purchase oscillometric monitors that measure BP on the upper arm with an appropriate cuff size and that have been shown to be accurate according to standard international protocols. They should be shown how to use them by their healthcare providers; (3) Two to 3 readings should be taken while the subject is resting in the seated position, both in the morning and at night, over a period of 1 week. A total of Ն12 readings are recommended for making clinical decisions; (4) HBPM is indicated in patients with newly diagnosed or suspected hypertension, in whom it may distinguish between white-coat and sustained hypertension. If the results are equivocal, ambulatory BP monitoring may help to establish the diagnosis; (5) In patients with prehypertension, HBPM may be useful for detecting masked hypertension; (6) HBPM is recommended for evaluating the response to any type of antihypertensive treatment and may improve adherence; (7) The target HBPM goal for treatment is Ͻ135/85 mm Hg or Ͻ130/80 mm Hg in high-risk patients; (8) HBPM is useful in the elderly, in whom both BP variability and the white-coat effect are increased; (9) HBPM is of value in patients with diabetes, in whom tight BP control is of paramount importance; (10) Other populations in whom HBPM may be beneficial include pregnant women, children, and patients with kidney disease; and (11) HBPM has the potential to improve the quality of care while reducing costs and should be reimbursed. (Hypertension. 2008;52:10-29.)

show abstract

Section: Health and Economic Consequences Of Hypertension And Its Inamentioning

confidence: 99%

Call to Action on Use and Reimbursement for Home Blood Pressure Monitoring

Pickering¹,

Miller

Ogedegbe³

et al. 2008

Hypertension

487

235

View full text Add to dashboard Cite

show abstract

“…Data from the Framingham study showed that only 25% of the men and 38% of the women survived after 5 years (Kannel, 1999). However, the incidence of CHF seems to be decreasing or plateauing out and the prognosis has improved particularly among patients < 60 years during the past decade (Stewart et al, 2001;Schaufelberger et al, 2004).…”

Section: Chronic Heart Failurementioning

confidence: 99%

Fatigue is a Prevalent and Severe Symptom Associated with Uncertainty and Sense of Coherence in Patients with Chronic Heart Failure

Falk

Swedberg

Gaston‐Johansson

et al. 2007

European Journal of Cardiovascular Nursing

102

View full text Add to dashboard Cite

Although fatigue is a prevalent and distressing symptom in patients with chronic heart failure (CHF), it is an underestimated problem in the care of patients, and consequently, insuffi ciently investigated. The primary aim of this thesis was, therefore, to advance the knowledge from the patients' perspective by describing characteristics of the fatigue experience and its consequences in daily life in patients with CHF. A secondary aim was to investigate the relationships between fatigue and selected physiological and psychological factors associated with fatigue. Both quantitative and qualitative methods have been used and three samples of patients have been interviewed on different occasions. In two of the quantitative studies 93 patients, and in another study 112 patients, consecutively included, were interviewed at the hospital. Fifteen patients were included in the qualitative study. These 15 participants were enrolled when they visited an outpatient clinic and most of them were interviewed in their homes. These interviews were supplemented with the content of an Internet discussion with persons living with CHF.The results of the studies indicated that fatigue embraces the individual's body, emotions and cognitive abilities, forcing the person to physical restrictions that, in turn, perpetuate emotional discomfort. However, the physical sensation of fatigue followed by functional limitations seemed to be the most prevalent and distressing experience in patients with CHF. The patients described fatigue as lacking strength, which was associated in connection with physical efforts and lacking energy, viewed as an annoying sensation after both mental and physical strain. Another dimension of fatigue was described as being sleepy, often with a rapid and unforeseen onset. Consequences of fatigue, such as refraining from daily chores, denying oneself opportunities for rejoice and social isolation, further exaggerated the experience of fatigue. Restorative activities that engaged, absorbed or distracted the patients counteracted these negative consequences. Depressed mood was related to those fatigue dimensions that compromised functional ability and motivation to start any activities, whereas anxiety was associated with cognitive impairment. Feelings of uncertainty were related to physical tiredness, possibly infl icted by limitations in performing activities. Symptom distress that was caused by a number of reported symptoms other than fatigue had a diminutive infl uence on fatigue and separate symptoms that were associated with fatigue were, with the exception of breathlessness, not the fi rst and most pressing symptom reported by the patients. Anemic patients reported more fatigue compared with non-anemic patients and functional status, according to the New York Heart Association (NYHA) functional classifi cation criteria, was associated with those fatigue dimensions that encompassed physical tiredness and reduced functioning.The fi ndings provide new insights on the characteristics of fatigue and its con...

show abstract

“…In the United States alone, approximately 5 million patients have CHF, which accounts for 20% of all hospitalizations among patients over the age of 65 years. 1 Deciphering the pathophysiological mechanisms of CHF and its complications is therefore imperative for the development of new therapies for improving the disease outcome. 2 In addition to myocardial dysfunction, the kidney plays a major role in the pathophysiology of CHF, 3,4 in which impaired renal function and reduced glomerular filtration rate (GFR) are considered to be strong independent predictors of death in patients with CHF.…”

mentioning

confidence: 99%

TVP1022 Attenuates Cardiac Remodeling and Kidney Dysfunction in Experimental Volume Overload-Induced Congestive Heart Failure

Abassi¹,

Barac²,

Kostin³

et al. 2011

Circ: Heart Failure

View full text Add to dashboard Cite

Background-Despite the availability of many pharmacological and mechanical therapies, the mortality rate among patients with congestive heart failure (CHF) remains high. We tested the hypothesis that TVP1022 (the S-isomer of rasagiline; Azilect), a neuroprotective and cytoprotective molecule, is also cardioprotective in the settings of experimental CHF in rats. Methods and Results-In rats with volume overload-induced CHF, we investigated the therapeutic efficacy of TVP1022 (7.5 mg/kg) on cardiac function, structure, biomarkers, and kidney function. Treatment with TVP1022 for 7 days before CHF induction prevented the increase in left ventricular end-diastolic area and end-systolic area, and the decrease in fractional shortening measured 14 days after CHF induction. Additionally, TVP1022 pretreatment attenuated CHF-induced cardiomyocyte hypertrophy, fibrosis, plasma and ventricular B-type natriuretic peptide levels, and reactive oxygen species expression. Further, in CHF rats, TVP1022 decreased cytochrome c and caspase 3 expression, thereby contributing to the cardioprotective efficacy of the drug. TVP1022 also enhanced the urinary Na ϩ excretion and improved the glomerular filtration rate. Similar cardioprotective effects were obtained when TVP1022 was given to rats after CHF induction. Conclusions-TVP1022 attenuated the adverse functional, structural, and molecular alterations in CHF, rendering this drug a promising candidate for improving cardiac and renal function in this disease state. (Circ Heart Fail. 2011;4:463-473.)

show abstract

Current status of the epidemiology of heart failure

Cited by 17 publications

References 30 publications

Call to Action on Use and Reimbursement for Home Blood Pressure Monitoring

Call to Action on Use and Reimbursement for Home Blood Pressure Monitoring

Fatigue is a Prevalent and Severe Symptom Associated with Uncertainty and Sense of Coherence in Patients with Chronic Heart Failure

TVP1022 Attenuates Cardiac Remodeling and Kidney Dysfunction in Experimental Volume Overload-Induced Congestive Heart Failure

Contact Info

Product

Resources

About